# OnCo record inxmed (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/inxmed/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "inxmed" ;
  schema:name "InxMed"@en ;
  schema:alternateName "InxMed (Shanghai) Co., Ltd."@en, "应世生物"@en, "InxMed (Shanghai)"@en, "inxmed-shanghai"@en ;
  schema:description "InxMed is a Shanghai biotechnology company developing IN10018 (ifebemtinib), a focal adhesion kinase inhibitor, which is in a phase 3 trial with the KRAS G12C inhibitor garsorasib against standard therapy in KRAS G12C-mutant lung cancer."@en ;
  schema:url <https://onco.cc/companies/inxmed/>, <https://www.inxmed.com/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://www.inxmed.com/>, <https://clinicaltrials.gov/search?lead=InxMed> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "CN" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/sclc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:drugs <https://onco.cc/drugs/in10018/> ;
  onco:trials <https://onco.cc/trials/nct07174908/>, <https://onco.cc/trials/nct05994131/>, <https://onco.cc/trials/nct05827796/>, <https://onco.cc/trials/nct06014528/>, <https://onco.cc/trials/nct06030258/>, <https://onco.cc/trials/nct05551507/> .